DiaMedica Therapeutics (DMAC) Cash from Financing Activities (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Cash from Financing Activities of $417000.0 for Q1 2026, up 358.24% year-over-year from $91000.0 in Q1 2025, and down 96.55% quarter-over-quarter from $12.1 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Cash from Financing Activities (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $417000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 358.24% year-over-year to $417000.0; the TTM figure through Mar 2026 stood at $44.2 million (up 265.73% YoY), while the FY2025 annual figure was $43.9 million, up 265.82% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $417000.0, down from $12.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $36.8 million in Q2 2023, with the low at -$6000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $91000.0 (2025), against an average of $5.5 million.
- Peak annual rise in Cash from Financing Activities reached 1842600.0% in 2023, while the deepest fall reached 200.0% in 2023.
- DiaMedica Therapeutics' Cash from Financing Activities stood at -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023, then soared by 12100.0% to $120000.0 in 2024, then jumped by 9975.83% to $12.1 million in 2025, then plunged by 96.55% to $417000.0 in 2026.
- Business Quant data shows DMAC's Cash from Financing Activities at $417000.0 in Q1 2026, $12.1 million in Q4 2025, and $31.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 132,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132,000.00 |
| Jun 30, 2026 | 132,000.00 |
| Mar 31, 2026 | 417,000.00 |
| Mar 31, 2026 | 417,000.00 |
| Dec 31, 2025 | 12.09 Mn |
| Dec 31, 2025 | 12.09 Mn |
| Sep 30, 2025 | 31.53 Mn |
| Sep 30, 2025 | 31.53 Mn |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 120,000.00 |
| Dec 31, 2024 | 120,000.00 |
| Sep 30, 2024 | 123,000.00 |
| Sep 30, 2024 | 123,000.00 |
| Jun 30, 2024 | 11.75 Mn |
| Jun 30, 2024 | 11.75 Mn |
| Mar 31, 2024 | -1,000.00 |
| Mar 31, 2024 | -1,000.00 |